Science and Technology › Biotechnology

Bioeconomy, biomanufacturing and biosafety

The bioeconomy and its safeguards: biomanufacturing and synthetic biology, the policies and bodies that fund them, biosafety laboratories and the rules on dual use research. It serves GS3 answers on biotechnology.

Showing 1 of 1 article, those that changed from 1 to 31 July 2026.Show all

India's bioeconomy

Prelims and Mains

The bioeconomy is the part of the economy built on biological resources and biotechnology, from vaccines and biofuels to industrial enzymes.

India's claim to be the world's largest vaccine producer rests on volume rather than value.

What changed

17 Jul 2026
- A NITI Aayog roadmap proposes a ₹50,000 crore BioEconomy Growth Fund for 2026 to 35, to take the bioeconomy to about $691 billion by 2035.
- It also proposes six national missions, including GeneIndia for gene and cell therapies and AgriBio 2.0 for gene edited crops.
- Under the BioE3 policy of 2024, biofoundries and biomanufacturing facilities have been funded, and a strain resource centre supplies indigenous production microbes.
The Hindu, 17 Jul 2026: NITI Aayog suggests ₹50,000-crore fund for biotech growth (opens in a new tab) · PIB, 16 Jul 2026: Government Focuses on Building Sovereign Biotechnology Ecosystem Through Talent, Innovation and Industry Partnerships: Dr Jitendra Singh (opens in a new tab) · PIB, 23 Jul 2026: PARLIAMENT QUESTION: IMPLEMENTATION OF BIOE3 POLICY (opens in a new tab)